Under the "Healthy China" strategy, China's continuous glucose monitoring (CGM) industry is benefiting from both policy and market advantages. The state has clearly supported the localization of high-end medical devices through multiple plans, while the NMPA has established expedited approval channels for innovative CGM products. At least three minimally invasive products are expected to be accelerated for market entry by 2025.
The continuous expansion of medical insurance coverage has become a key driver. Starting in 2025, many regions will include continuous glucose monitoring (CGM) in outpatient chronic disease reimbursement, with employee medical insurance covering 60%-70% of costs and resident medical insurance covering 50%-60%, with an annual cap of 3,000 yuan. The popularization of primary care and advancements in remote management have driven market growth. In 2024, the domestic medical CGM market reached 7.68 billion yuan, a 28.5% year-on-year increase, and is expected to rise to 9.83 billion yuan in 2025. Local enterprises like Meiki Medical, through technological breakthroughs, are projected to capture 42% of the domestic market, with prices at just 50%-70% of imported products.
